amikacin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, kanamycin and bekanamycin derivatives (obtained from Streptomyces kanamyceticus)	157	37517-28-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: amikacin amicacin amikacillin arikace lukadin amikacin sulfate amikacin hydrate	A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics. Molecular weight: 585.61 Formula: C22H43N5O13 CLOGP: -4.12 LIPINSKI: 3 HAC: 18 HDO: 13 TPSA: 331.94 ALOGS: -1.07 ROTB: 10 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
1	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	98 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	25.61 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	0 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.16 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	1.10 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.88 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2.40 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Jan. 22, 1981	FDA	APOTHECON

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug resistance	263.98	19.32	111	10486	17257	46658208
Pathogen resistance	156.80	19.32	57	10540	6003	46669462
Drug reaction with eosinophilia and systemic symptoms	132.79	19.32	83	10514	29465	46646000
Septic shock	128.85	19.32	106	10491	57787	46617678
Multiple organ dysfunction syndrome	128.50	19.32	101	10496	51609	46623856
Deafness	114.64	19.32	61	10536	16007	46659458
Ototoxicity	100.50	19.32	27	10570	1042	46674423
Dysphonia	84.70	19.32	70	10527	38344	46637121
Thrombocytopenia	83.56	19.32	122	10475	126459	46549006
Klebsiella infection	79.69	19.32	36	10561	6626	46668839
Geotrichum infection	79.51	19.32	19	10578	453	46675012
Systemic candida	75.59	19.32	27	10570	2700	46672765
Toxic skin eruption	74.45	19.32	42	10555	12345	46663120
Mycobacterium abscessus infection	74.18	19.32	19	10578	607	46674858
Pseudomonas infection	72.29	19.32	38	10559	9720	46665745
Eosinophilia	66.81	19.32	46	10551	19171	46656294
Sepsis	64.81	19.32	113	10484	135901	46539564
Rash maculo-papular	61.86	19.32	51	10546	27823	46647642
Tinnitus	60.09	19.32	50	10547	27623	46647842
Aphonia	59.02	19.32	31	10566	7914	46667551
Febrile neutropenia	54.98	19.32	86	10511	94541	46580924
Nephropathy toxic	52.30	19.32	28	10569	7426	46668039
Myelosuppression	51.44	19.32	28	10569	7675	46667790
Acute kidney injury	51.41	19.32	143	10454	235712	46439753
Toxic epidermal necrolysis	49.93	19.32	41	10556	22237	46653228
Hepatotoxicity	49.81	19.32	43	10554	24966	46650499
Paradoxical drug reaction	49.23	19.32	19	10578	2357	46673108
Haemoptysis	48.10	19.32	43	10554	26146	46649319
Hepatocellular injury	47.47	19.32	45	10552	29477	46645988
Mycobacterium avium complex infection	47.23	19.32	19	10578	2629	46672836
Pain	46.95	19.32	25	10572	476923	46198542
Encephalopathy	46.18	19.32	47	10550	33542	46641923
Enterococcal infection	45.55	19.32	25	10572	6962	46668503
Pyrexia	44.22	19.32	176	10421	348626	46326839
Bronchopulmonary aspergillosis	43.91	19.32	25	10572	7471	46667994
Fatigue	43.10	19.32	45	10552	608652	46066813
Candida infection	41.80	19.32	37	10560	22203	46653262
Osteomyelitis bacterial	39.40	19.32	9	10588	175	46675290
Acinetobacter infection	39.11	19.32	14	10583	1408	46674057
Immune reconstitution inflammatory syndrome	38.75	19.32	21	10576	5704	46669761
Bacteraemia	38.00	19.32	29	10568	14150	46661315
Off label use	36.92	19.32	177	10420	379664	46295801
Product use in unapproved indication	36.60	19.32	70	10527	90203	46585262
Acute respiratory distress syndrome	36.36	19.32	34	10563	21888	46653577
Fall	35.79	19.32	15	10582	329082	46346383
Clostridium difficile colitis	35.13	19.32	31	10566	18522	46656943
Multiple-drug resistance	34.33	19.32	15	10582	2550	46672915
Mycobacterial infection	33.62	19.32	13	10584	1620	46673845
Nosocomial infection	33.61	19.32	13	10584	1622	46673843
Arthralgia	33.14	19.32	21	10576	364582	46310883
Sputum increased	32.71	19.32	13	10584	1743	46673722
Mucormycosis	32.62	19.32	14	10583	2278	46673187
Cholestasis	32.27	19.32	35	10562	26858	46648607
Acute generalised exanthematous pustulosis	31.47	19.32	22	10575	9383	46666082
Hepatitis	30.34	19.32	37	10560	32178	46643287
Herpes simplex hepatitis	30.15	19.32	8	10589	294	46675171
Hypertransaminasaemia	29.93	19.32	15	10582	3473	46671992
Retinal ischaemia	29.74	19.32	8	10589	310	46675155
Haemorrhage intracranial	29.73	19.32	24	10573	12700	46662765
Neutropenic colitis	29.70	19.32	13	10584	2219	46673246
Antithrombin III	29.01	19.32	7	10590	174	46675291
Leukopenia	27.70	19.32	53	10544	68290	46607175
Hepatosplenic candidiasis	27.56	19.32	7	10590	216	46675249
Pancreatitis acute	27.47	19.32	31	10566	24841	46650624
Neutropenia	27.43	19.32	83	10514	143121	46532344
Cough	27.35	19.32	114	10483	230135	46445330
Headache	26.90	19.32	42	10555	478310	46197155
Klebsiella bacteraemia	26.51	19.32	10	10587	1166	46674299
Granulomatous liver disease	26.03	19.32	9	10588	817	46674648
Coagulopathy	25.63	19.32	26	10571	18473	46656992
Granulomatosis with polyangiitis	25.63	19.32	11	10586	1791	46673674
Dysbiosis	25.52	19.32	8	10589	534	46674931
Vulvovaginitis	25.36	19.32	7	10590	299	46675166
Polyneuropathy	25.18	19.32	21	10576	11623	46663842
Rhinocerebral mucormycosis	24.72	19.32	6	10591	153	46675312
Kussmaul respiration	24.72	19.32	6	10591	153	46675312
Pancytopenia	24.08	19.32	57	10540	85001	46590464
Chemotherapeutic drug level increased	23.82	19.32	6	10591	179	46675286
Deafness neurosensory	23.70	19.32	14	10583	4480	46670985
Hyperlactacidaemia	23.45	19.32	11	10586	2204	46673261
Corneal opacity	23.38	19.32	8	10589	704	46674761
Febrile bone marrow aplasia	22.84	19.32	16	10581	6846	46668619
Mycobacterium chelonae infection	22.68	19.32	7	10590	444	46675021
Overgrowth fungal	22.64	19.32	5	10592	83	46675382
Nasopharyngitis	22.33	19.32	4	10593	153994	46521471
Neonatal respiratory distress syndrome	22.05	19.32	11	10586	2522	46672943
Pain in extremity	22.00	19.32	16	10581	258664	46416801
Guillain-Barre syndrome	21.97	19.32	12	10585	3310	46672155
Agranulocytosis	21.74	19.32	26	10571	22159	46653306
Retinal artery occlusion	21.40	19.32	9	10588	1393	46674072
Product administered to patient of inappropriate age	21.40	19.32	11	10586	2685	46672780
Acute hepatic failure	20.96	19.32	21	10576	14700	46660765
Endocarditis candida	20.78	19.32	4	10593	32	46675433
Malaise	20.64	19.32	27	10570	331205	46344260
Infective pulmonary exacerbation of cystic fibrosis	20.34	19.32	18	10579	10789	46664676
Bone marrow failure	20.10	19.32	29	10568	29640	46645825
Electrocardiogram QT prolonged	19.81	19.32	39	10558	51286	46624179
Lower respiratory tract infection bacterial	19.78	19.32	6	10591	359	46675106
Tinea versicolour	19.47	19.32	4	10593	46	46675419

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Ototoxicity	215.87	17.97	60	13070	1336	29938012
Drug resistance	210.37	17.97	123	13007	20010	29919338
Septic shock	173.30	17.97	174	12956	63433	29875915
Pathogen resistance	105.63	17.97	58	13072	8352	29930996
Product use in unapproved indication	105.51	17.97	145	12985	73548	29865800
Mycobacterium abscessus infection	103.55	17.97	28	13102	560	29938788
Deafness	92.02	17.97	57	13073	10268	29929080
Drug reaction with eosinophilia and systemic symptoms	88.79	17.97	84	13046	28404	29910944
Multiple organ dysfunction syndrome	82.06	17.97	119	13011	63368	29875980
Thrombocytopenia	67.37	17.97	170	12960	136874	29802474
Fatigue	63.17	17.97	31	13099	320642	29618706
Mycobacterium chelonae infection	62.44	17.97	19	13111	586	29938762
Acute kidney injury	61.74	17.97	260	12870	273582	29665766
Rash maculo-papular	60.89	17.97	65	13065	25353	29913995
Electrocardiogram QT prolonged	59.66	17.97	76	13054	35759	29903589
Fall	58.41	17.97	6	13124	181866	29757482
Drug ineffective	57.50	17.97	297	12833	340090	29599258
Toxic skin eruption	53.73	17.97	42	13088	10973	29928375
Enterococcal infection	50.49	17.97	36	13094	8188	29931160
Brain abscess	49.59	17.97	24	13106	2657	29936691
Tuberculosis	48.77	17.97	35	13095	8042	29931306
Febrile bone marrow aplasia	44.16	17.97	33	13097	8064	29931284
Death	43.41	17.97	56	13074	357227	29582121
Deafness neurosensory	43.00	17.97	21	13109	2372	29936976
Candida infection	41.66	17.97	42	13088	15320	29924028
Blood pressure measurement	39.80	17.97	10	13120	148	29939200
Acute respiratory distress syndrome	39.40	17.97	50	13080	23422	29915926
Multiple-drug resistance	38.90	17.97	21	13109	2920	29936428
Hepatotoxicity	37.56	17.97	43	13087	18102	29921246
Nocardiosis	35.75	17.97	21	13109	3434	29935914
Aspergillus infection	35.44	17.97	32	13098	10182	29929166
Deafness bilateral	33.87	17.97	14	13116	1068	29938280
Hypertransaminasaemia	33.47	17.97	21	13109	3864	29935484
Pain	33.43	17.97	17	13113	172624	29766724
Pseudomonas infection	32.80	17.97	31	13099	10451	29928897
Immune reconstitution inflammatory syndrome	32.54	17.97	29	13101	9072	29930276
Pyrexia	32.32	17.97	230	12900	294259	29645089
Treatment failure	32.29	17.97	56	13074	34623	29904725
Myocardial infarction	31.72	17.97	8	13122	125617	29813731
Myelosuppression	31.62	17.97	26	13104	7296	29932052
Acute generalised exanthematous pustulosis	31.37	17.97	24	13106	6074	29933274
Vascular pseudoaneurysm thrombosis	31.14	17.97	7	13123	62	29939286
Cholestasis	31.06	17.97	46	13084	24904	29914444
Leukopenia	31.06	17.97	73	13057	56086	29883262
Acoustic neuroma	31.03	17.97	8	13122	132	29939216
Nephropathy toxic	30.53	17.97	30	13100	10609	29928739
Hepatocellular injury	30.34	17.97	46	13084	25425	29913923
Off label use	29.87	17.97	199	12931	249091	29690257
Eosinophilia	29.25	17.97	42	13088	22118	29917230
Hypoacusis	28.41	17.97	33	13097	14106	29925242
Hypofibrinogenaemia	28.25	17.97	14	13116	1631	29937717
Inflammatory marker increased	26.88	17.97	17	13113	3171	29936177
Mycobacterium avium complex infection	26.80	17.97	16	13114	2695	29936653
Klebsiella infection	26.74	17.97	23	13107	6864	29932484
Pancytopenia	26.70	17.97	90	13040	84962	29854386
Lymphocyte count decreased	26.45	17.97	37	13093	19018	29920330
Drug ineffective for unapproved indication	26.35	17.97	28	13102	10852	29928496
Linear IgA disease	25.65	17.97	13	13117	1589	29937759
Incision site pain	25.65	17.97	14	13116	1990	29937358
Red blood cells urine positive	25.53	17.97	13	13117	1604	29937744
Stenotrophomonas infection	25.48	17.97	13	13117	1611	29937737
Cardiac valve vegetation	25.30	17.97	9	13121	456	29938892
Bronchopulmonary aspergillosis	25.23	17.97	29	13101	12255	29927093
Hyperbilirubinaemia	25.18	17.97	34	13096	16908	29922440
Protein urine present	25.01	17.97	19	13111	4756	29934592
Sepsis	24.71	17.97	128	13002	146267	29793081
Systemic candida	23.96	17.97	15	13115	2749	29936599
Posterior reversible encephalopathy syndrome	23.96	17.97	24	13106	8683	29930665
Candida sepsis	23.90	17.97	11	13119	1088	29938260
Mycobacterium fortuitum infection	23.58	17.97	7	13123	198	29939150
Toxic neuropathy	23.12	17.97	8	13122	373	29938975
Weight bearing difficulty	23.00	17.97	10	13120	865	29938483
Respiratory distress	22.92	17.97	47	13083	32925	29906423
Allodynia	22.59	17.97	9	13121	624	29938724
Agranulocytosis	22.50	17.97	37	13093	21905	29917443
Disseminated intravascular coagulation	22.21	17.97	37	13093	22134	29917214
Sepsis neonatal	21.89	17.97	7	13123	255	29939093
Sputum purulent	21.75	17.97	8	13122	446	29938902
Scedosporium infection	21.53	17.97	9	13121	706	29938642
Hepatitis fulminant	21.35	17.97	16	13114	3925	29935423
Dehydration	21.28	17.97	14	13116	123525	29815823
Aeromonas infection	21.26	17.97	7	13123	280	29939068
Fusarium infection	21.12	17.97	10	13120	1054	29938294
Headache	20.62	17.97	30	13100	182276	29757072
Vestibular disorder	20.42	17.97	9	13121	804	29938544
Malaise	20.37	17.97	26	13104	166936	29772412
Cardiac failure congestive	20.12	17.97	6	13124	84401	29854947
Meningitis tuberculous	20.05	17.97	8	13122	557	29938791
Dizziness	19.30	17.97	35	13095	194874	29744474
Product dose omission issue	19.30	17.97	8	13122	91623	29847725
Mucormycosis	19.25	17.97	17	13113	5251	29934097
Febrile neutropenia	19.18	17.97	95	13035	106598	29832750
Gallstone ileus	19.16	17.97	4	13126	24	29939324
Hepatosplenic candidiasis	18.96	17.97	6	13124	211	29939137
Shock	18.82	17.97	35	13095	22824	29916524
Flavobacterium infection	18.78	17.97	5	13125	94	29939254
Syncope	18.56	17.97	7	13123	84896	29854452
Acinetobacter infection	18.55	17.97	9	13121	1001	29938347
Pericarditis tuberculous	18.44	17.97	5	13125	101	29939247
C-reactive protein increased	18.30	17.97	51	13079	43422	29895926
Neuropathy peripheral	18.21	17.97	70	13060	70405	29868943
Fungal sepsis	18.17	17.97	8	13122	713	29938635
Skin hyperpigmentation	18.13	17.97	13	13117	2981	29936367
Pulmonary cavitation	18.12	17.97	8	13122	718	29938630
Renal tubular disorder	17.99	17.97	16	13114	4990	29934358

Pharmacologic Action:

Source	Code	Description
ATC	D06AX12	DERMATOLOGICALS ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE ANTIBIOTICS FOR TOPICAL USE Other antibiotics for topical use
ATC	J01GB06	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE AMINOGLYCOSIDE ANTIBACTERIALS Other aminoglycosides
ATC	J01RA06	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE COMBINATIONS OF ANTIBACTERIALS Combinations of antibacterials
ATC	S01AA21	SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFECTIVES Antibiotics
FDA CS	M0000946	Aminoglycosides
FDA EPC	N0000175477	Aminoglycoside Antibacterial
CHEBI has role	CHEBI:33281	antibiotics
CHEBI has role	CHEBI:36047	antibacterial drugs
CHEBI has role	CHEBI:61015	nephrotoxins
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Septicemia due to Escherichia coli	indication	9323009
Bacterial septicemia	indication	10001005	DOID:0040085
Infection due to Pseudomonas aeruginosa	indication	11218009
Staphylococcal meningitis	indication	12166008
Infection of skin AND/OR subcutaneous tissue	indication	19824006
Staphylococcal pneumonia	indication	22754005
Pneumonia due to Pseudomonas	indication	41381004
Pneumonia due to Escherichia coli	indication	51530003
Bacterial pneumonia	indication	53084003	DOID:874
Osteomyelitis	indication	60168000
Infection due to Escherichia coli	indication	71057007
Bacterial infection due to Serratia	indication	71120004
Rhinoscleroma	indication	72409005	DOID:11336
Septicemia due to Serratia	indication	82091000
Cholangitis	indication	82403002	DOID:9446
Bacterial meningitis	indication	95883001	DOID:9470
Infection of bone	indication	111253001
Staphylococcal septicemia	indication	111821004
Infectious disease of abdomen	indication	128070006
Infection due to Enterobacteriaceae	indication	128945009
Bacterial infection due to Klebsiella pneumoniae	indication	186435004
Escherichia coli meningitis	indication	192655005
Proteus pneumonia	indication	195888009
Sepsis of the newborn	indication	206376005
Neonatal pneumonia	indication	233619008
Diverticulitis of gastrointestinal tract	indication	271366000
Neonatal meningitis	indication	276674008
Proteus septicemia	indication	300986008
Escherichia coli urinary tract infection	indication	301011002
Proteus meningitis	indication	302877009
Bacterial urinary infection	indication	312124009
Infectious disorder of joint	indication	363162000
Meningitis due to Klebsiella mobilis	indication	420585007
Nosocomial pneumonia	indication	425464007
Bacterial meningitis due to Gram-negative bacteria	indication	425887005
Pneumonia due to Gram negative bacteria	indication	430395005
Sepsis due to Pseudomonas	indication	448813005
Sepsis due to Gram negative bacteria	indication	449082003
Urinary tract infection caused by Klebsiella	indication	369001000119100
Skin and Skin Structure Serratia Infection	indication
Pseudomonas Aeruginosa Biliary Tract Infection	indication
Klebsiella Septicemia	indication
Complicated Urinary Tract Infections	indication
Complicated UTI with Pseudomonas Aeruginosa	indication
Pseudomonas Aeruginosa Meningitis	indication
Pseudomonas Aeruginosa Osteomyelitis	indication
Skin and Skin Structure Proteus Infection	indication
Serratia Meningitis	indication
Skin and Skin Structure Staphylococcus Infection	indication
Enterobacter Meningitis	indication
Skin and Skin Structure Pseudomonas Aeruginosa Infection	indication
Burn Wound Infections	indication
Gram-Negative Aerobic Bacillary Pneumonia	indication
Complicated Bacterial Peritonitis	indication
Complicated Proteus UTI	indication
Complicated Urinary Tract Infection due to Acinetobacter	indication
Pseudomonas Aeruginosa Joint Infection	indication
Serratia Osteomyelitis	indication
Serratia Complicated UTI	indication
Enterobacter Pneumonia	indication
Necrotizing enterocolitis in fetus OR newborn	off-label use	2707005
Pyrexia of unknown origin	off-label use	7520000
Enteric campylobacteriosis	off-label use	18081009
Acute tuberculosis	off-label use	25629007
Pseudotuberculosis	off-label use	36753006
Infection by Yersinia enterocolitica	off-label use	80960004
Pulmonary tuberculosis	off-label use	154283005	DOID:2957
Synergy for Neonatal Meningitis	off-label use
Citrobacter Complicated UTI	off-label use
Synergy for Group B Streptococcal Septicemia	off-label use
Citrobacter Septicemia	off-label use
Citrobacter Meningitis	off-label use
Synergy for Bacterial Meningitis	off-label use
Citrobacter Osteomyelitis	off-label use
Synergy for P. Aeruginosa Infection in Cystic Fibrosis	off-label use
Listeria Monocytogenes Septicemia	off-label use
Skin and Skin Structure Citrobacter Infection	off-label use
Skin and Skin Structure Acinetobacter Infection	off-label use
Synergy for Staphylococcal Infections	off-label use
Citrobacter Pneumonia	off-label use
Synergy for Nosocomial Pneumonia due to Pseudomonas Aeruginosa	off-label use
Synergy for Staphylococcal Endocarditis	off-label use
Hypocalcemia	contraindication	5291005
Parkinsonism	contraindication	32798002
Dehydration	contraindication	34095006
Tinnitus	contraindication	60862001
Kidney disease	contraindication	90708001	DOID:557
Myasthenia gravis	contraindication	91637004	DOID:437
Pregnancy, function	contraindication	289908002
Vertigo	contraindication	399153001
Disorder of the 8th Cranial Nerve	contraindication
Amikacin Toxicity	contraindication
Infant Botulism	contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	12.04	acidic
pKa2	12.95	acidic
pKa3	13.39	acidic
pKa4	13.72	acidic
pKa5	9.4	Basic
pKa6	7.84	Basic
pKa7	7.41	Basic
pKa8	6.86	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
EQ 590MG BASE/8.4ML	ARIKAYCE KIT	INSMED INC	N207356	Sept. 28, 2018	RX	SUSPENSION, LIPOSOMAL	INHALATION	Sept. 28, 2025	TX OF MAC LUNG DISEASE IN ADULTS WITH LIMITED OR NO ALTERNULLTIVE TX OPTIONS AS PART OF A COMBO ANTIBACTERIAL DRUG REGIMEN WHO DO NOT ACHIEVE NEGATIVE SPUTUM CULTURES AFTER A MINIMUM OF 6 CONSECUTIVE MONTHS OF A MULTIDRUG BACKGROUND REGIMEN THERAPY
EQ 590MG BASE/8.4ML	ARIKAYCE KIT	INSMED INC	N207356	Sept. 28, 2018	RX	SUSPENSION, LIPOSOMAL	INHALATION	Sept. 28, 2030	GENERATING ANTIBIOTIC INCENTIVES NOW

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)	Enzyme		O32553_ECOLX		Km	4.20		WOMBAT-PK

External reference:

ID	Source
84319SGC3C	UNII
4019602	VUID
N0000147698	NUI
D00865	KEGG_DRUG
39831-55-5	SECONDARY_CAS_RN
C0002499	UMLSCUI
CHEBI:2637	CHEBI
AKN	PDB_CHEM_ID
CHEMBL177	ChEMBL_ID
CHEMBL1164318	ChEMBL_ID
CHEMBL4208954	ChEMBL_ID
DB00479	DRUGBANK_ID
D000583	MESH_DESCRIPTOR_UI
37768	PUBCHEM_CID
3492	INN_ID
10894	IUPHAR_LIGAND_ID
641	RXNORM
2863	MMSL
35287	MMSL
4165	MMSL
d00087	MMSL
002781	NDDF
004899	NDDF
1269009	SNOMEDCT_US
387266001	SNOMEDCT_US
48836000	SNOMEDCT_US
4018137	VANDF
4019602	VANDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Amikacin Sulfate	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6166	INJECTION	250 mg	INTRAMUSCULAR	ANDA	22 sections
Amikacin Sulfate	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6167	INJECTION	250 mg	INTRAMUSCULAR	ANDA	22 sections
Amikacin Sulfate	HUMAN PRESCRIPTION DRUG LABEL	1	0703-9032	INJECTION, SOLUTION	500 mg	INTRAMUSCULAR	ANDA	20 sections
Amikacin Sulfate	HUMAN PRESCRIPTION DRUG LABEL	1	0703-9040	INJECTION, SOLUTION	1 g	INTRAMUSCULAR	ANDA	20 sections
Amikacin Sulfate	HUMAN PRESCRIPTION DRUG LABEL	1	23155-290	INJECTION, SOLUTION	250 mg	INTRAMUSCULAR	ANDA	20 sections
Amikacin Sulfate	HUMAN PRESCRIPTION DRUG LABEL	1	23155-785	INJECTION, SOLUTION	500 mg	INTRAMUSCULAR	ANDA	20 sections
Amikacin Sulfate	HUMAN PRESCRIPTION DRUG LABEL	1	23155-786	INJECTION, SOLUTION	1 g	INTRAMUSCULAR	ANDA	20 sections
amikacin sulfate	HUMAN PRESCRIPTION DRUG LABEL	1	25021-173	INJECTION, SOLUTION	250 mg	INTRAVENOUS	ANDA	23 sections
Amikacin Sulfate	HUMAN PRESCRIPTION DRUG LABEL	1	63323-815	INJECTION, SOLUTION	250 mg	INTRAVENOUS	ANDA	19 sections
Amikacin Sulfate Injection, 500 mg/2ml	HUMAN PRESCRIPTION DRUG LABEL	1	70297-996	INJECTION	500 mg	INTRAMUSCULAR	Export only
Amikacin Sulfate Injection, 500 mg/2ml	HUMAN PRESCRIPTION DRUG LABEL	1	71309-996	INJECTION	500 mg	INTRAMUSCULAR	Export only
ARIKAYCE	HUMAN PRESCRIPTION DRUG LABEL	1	71558-590	SUSPENSION	590 mg	RESPIRATORY (INHALATION)	NDA	33 sections